HC Wainwright Forecasts Stronger Earnings for Pharming Group

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Equities researchers at HC Wainwright raised their Q4 2025 earnings per share estimates for Pharming Group in a note issued to investors on Wednesday, February 4th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn $0.10 per share for the quarter, up from their previous forecast of $0.05. The consensus estimate for Pharming Group’s current full-year earnings is ($0.20) per share.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05. The firm had revenue of $97.30 million during the quarter, compared to analysts’ expectations of $98.22 million. Pharming Group had a return on equity of 0.46% and a net margin of 0.30%.

PHAR has been the topic of several other reports. Zacks Research cut shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Weiss Ratings restated a “hold (c-)” rating on shares of Pharming Group in a research report on Monday, December 22nd. Finally, Wall Street Zen raised shares of Pharming Group to a “strong-buy” rating in a research note on Saturday, December 27th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Pharming Group Trading Down 5.0%

Pharming Group stock opened at $16.04 on Friday. The stock has a 50-day moving average price of $17.77 and a 200 day moving average price of $15.25. Pharming Group has a 52 week low of $7.50 and a 52 week high of $21.34. The stock has a market cap of $1.13 billion, a PE ratio of -1,602.40 and a beta of -0.01. The company has a current ratio of 3.16, a quick ratio of 2.39 and a debt-to-equity ratio of 0.35.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 2,979 shares of the company’s stock, valued at approximately $32,000. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.